Hosseini S, Chamani J, Rahimi H, Azmoodeh N, Ghasemi F, Hassan Abadi P. An
In vitro Study on Curcumin Delivery by Nano-Micelles for Esophageal Squamous Cell Carcinoma (KYSE-30). rbmb.net. 2018; 6 (2) :137-143
URL:
http://rbmb.net/article-1-131-en.html
Department of Modern Sciences & Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract: (4663 Views)
Background: The incidence of esophageal squamous cell carcinoma (ESCC) is increasing, causing catastrophic health burdens on communities. Curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. The application of nano-carriers as drug delivery systems increases curcuminchr('39')s bioavailability. Cyclin D1 is overexpressed in ESCC and curcumin may change its expression.
Methods: In this study, the effect of SinaCurcumin®, a novel nano-micelle product containing 80 mg curcumin, on the growth of KYSE-30 cells and expression of cyclin D1, was investigated. Paclitaxel and Carboplatin served as reference drugs.
Results: Nano-curcumin increased cell cytotoxicity, decreased IC50, and down-regulated of cyclin D1. However, treatment of cells with nano-curcumin might result in multidrug resistance.
Conclusions: Nano-curcumin suppressed proliferation of KYSE-30 cells and expression of cyclin D1 although its use in combination with other chemotherapeutic agents requires further testing.
Type of Article:
Original Article |
Subject:
Molecular Biology Received: 2017/01/8 | Accepted: 2017/01/25 | Published: 2017/10/1